UCLA Medical Center: Division of Rheumatology
Welcome,         Profile    Billing    Logout  
 12 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fox, David
CONTROL-RA, NCT05306353: CD40L Antagonism in Rheumatoid Arthritis (RA)

Active, not recruiting
2
104
NA
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Rheumatoid Arthritis
08/25
03/26
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
McMahon, Maureen
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27
Raymond, Jennifer
NCT03793673: CoYoT1 to California

Completed
N/A
82
US
CoYoT1 Care, Standard Care
Children's Hospital Los Angeles, University of Southern California, Rutgers University
Type 1 Diabetes Mellitus
07/22
12/22
NCT05031429: Time Limited Eating in Type 1 Diabetes

Completed
N/A
12
US
Time Limited Eating
Children's Hospital Los Angeles
Type 1 Diabetes
06/23
06/23
CHLA-19-00062, NCT04190368: Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes

Active, not recruiting
N/A
79
US
Team Clinic Care, Standard Care
Children's Hospital Los Angeles, University of Southern California, Cedars-Sinai Medical Center
Type 1 Diabetes
11/24
12/24
NCT06348160: iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

Recruiting
N/A
192
US
iHERO Toolkit Resource
Julia Blanchette, The Leona M. and Harry B. Helmsley Charitable Trust
Type 1 Diabetes
03/26
03/26
DREAM, NCT06546930: Device Use Reimagined Through Education And Mentorship

Recruiting
N/A
120
US
DREAM intervention
University of California, San Francisco, Children's Hospital Los Angeles, University of California, Davis, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
05/26
05/26
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
Kafaja, Suzanne
NCT02541955: Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Recruiting
4
40
US
Acthar, Repository corticotropin injection
Veena Ranganath, MD, MS
Rheumatoid Arthritis (RA)
12/24
12/25
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
NCT02682511: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Recruiting
2
34
US, RoW
Oral Ifetroban, Ifetroban, Oral Placebo
Cumberland Pharmaceuticals
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
12/25
12/25
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Barroso, Nashla
NCT02682511: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Recruiting
2
34
US, RoW
Oral Ifetroban, Ifetroban, Oral Placebo
Cumberland Pharmaceuticals
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
12/25
12/25
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
NCT04765150: Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

Recruiting
N/A
275
US
3 Tesla Magnetic Resonance Imaging, 3 Tesla MRI, 3T MRI, Electronic Health Record Review
Jonsson Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Prostate Carcinoma
06/26
06/27
Arshad, Amina
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
Kim, Julia
PATENT-E, NCT05561114: Paclitaxel Coated Balloon for the Treatment of Chronic BEnigN STricture- Esophagus

Recruiting
3
198
US
GIE Medical ProTractX3 TTS DCB, Control
GIE Medical
Esophageal Stricture
07/25
12/29
ReBET, NCT03554356: Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

Recruiting
N/A
70
US
CryoBalloon Focal Ablation System
University of North Carolina, Chapel Hill, PENTAX of America, Inc., Johns Hopkins University
Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
12/26
12/26
SURVENT, NCT05753748: Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Recruiting
N/A
680
US
Endoscopic Eradication Therapy
University of Colorado, Denver, Baylor University, University of North Carolina, Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
02/28
02/28
Perry, Lucas
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
Ramirez, Belén
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24

Download Options